Sorted By:


This is not a special effect: New video shows the destruction of a rogue cell

PhRMA  |  Blog Post

Over the last decade, we’ve seen a number of advancements in treatments for RA, including a new first-in-class oral medicine offering greater convenience for patients.

Director– Policy and Research

PhRMA  |  PhRMA Career

The preferred candidate will bring substantive policy development and analytic experience, ideally in a legislative setting, as well as exceptional written and verbal communication skills, expertise in reviewing and interpreting in-depth policy analyses including trend reports and fiscal impact statements, and be focused, organized, detail-oriented, responsive and diplomatic.

4 Things to Know about the Medicare Part D Premium Announcement

PhRMA  |  Blog Post

The Medicare Trustees report that rebates on brand medicines are “substantial” and that average rebate levels have increased each year of the program.

PhRMA Statement Regarding White House Jobs Summit

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.

New medicines are part of the solution to hold down future health care costs

PhRMA  |  Blog Post

To learn more check out our International Costs in Context information.

Share the Savings

PhRMA  |  From PhRMA

A new analysis from Amundsen Consulting found more than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on the full list price.

PhRMA Statement on Senate HELP Committee Hearing on Securing the Pharmaceutical Supply Chain

PhRMA  |  Press Release

Consider the appropriateness of including new burdens on the import of materials for use in preclinical and clinical investigations.

Julie Ward

PhRMA  |  Biography

Julie Ward, Health Policy Director, The Arc, is responsible for representing The Arc before Congress and Federal agencies on health care reform, Medicaid, Medicare and related issues.

Morning Consult - PhRMA National Poll - 5.1.15

PhRMA  |  Fact Sheet

Morning Consult and PhRMA report on voters' opinions on patents and intellectual property issues on a national scale.

PhRMA Statement on Personalized Medicine Research

PhRMA  |  Press Release

“America’s biopharmaceutical research companies are ‘pushing strongly ahead’ in the world of personalized medicine research, the report emphasizes.

Washington State Research Institutions Have Conducted More Than 3,600 Clinical Trials of New Medicines Since 1999

PhRMA  |  Press Release

\ The report appendix offers URL codes for each Washington State trial still recruiting patients.

Visualizing Our Scope

PhRMA  |  Blog Post

But in the meantime, it's worth looking at the related report on the U.S. as a whole.

Improving PDMPs: Strengthening state tools to prevent prescription drug abuse

PhRMA  |  Blog Post

Provide Proactive Alerts and Dashboards: PDMPs should proactively send alerts and data should be packaged for physicians in easy-to-read reports based on thoughtful, evidence-based criteria and triggers.

Stand up for inventors of biologic drugs

From Hope To Cures  |  From Our Network

But what also built America was the ability to export its best ideas for the betterment of neighbors around the world and economic competitiveness.

PhRMA Statement on the President’s FY 2010 Budget Proposal

PhRMA  |  Press Release

Industry-wide research and investment reached a record $58.8 billion in 2007.

Medicare Monday: A closer look at Part B spending

PhRMA  |  Blog Post

That’s according to MedPAC and the Medicare Trustees report.

Medicare Monday: CMS withdraws Part B demo, takes positive step forward on CMMI

PhRMA  |  Blog Post

Originally put forward by the Center for Medicare and Medicaid Innovation (CMMI) in March 2016, the Part B Drug Payment Model, or Part B demo, proposed altering the way providers are reimbursed under Part B with a nearly nationwide, mandatory model that threatened access and quality of care for Medicare patients.

Ken Frazier

PhRMA  |  Biography

He also is a member of the American Academy of Arts and Sciences, the President’s Export Council, The Business Council, the Council of the American Law Institute and the American Bar Association.

Responsible Clinical Trial Data Sharing Is Enhancing Science and Improving Patient Health

PhRMA  |  Blog Post

The synopses of clinical study reports for clinical trials in patients submitted to the Food and Drug Administration, European Medicines Agency or national authorities of EU member states will be made publicly available upon the approval of a new medicine or new indication.

World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation

PhRMA  |  Blog Post

According to a 2017 Medicines in Development Report for HIV, there are 52 medicines and vaccines for HIV currently in development, either in clinical trials or awaiting review by the U.S.

Privacy Policy

Access Better Coverage  |  From PhRMA

We do not use this service to gather, request, record, require, collect or track any Internet users' personally identifiable information.

Focusing Payment and Delivery on Patients

PhRMA  |  Blog Post

PhRMA believes payment reform should increase the benefit individual patients receive from their health care, while also ensuring they are not forgotten in the process.

AstraZeneca’s Chip Davis Joins PhRMA To Assist Organization in Leadership Transition

PhRMA  |  Press Release

Industry-wide research and investment reached a record $65.2 billion in 2008.

Medicare Monday: What they’re saying about the CMS proposed Part B payment model

PhRMA  |  Blog Post

Also, rheumatologists argue that factoring in the Part B demonstration would distort physician comparisons in the Merit-Based Incentive Payment System, which will also be part of the new physician-pay scheme,” reports Inside Health Policy.

Medicare Monday: Did you know Medicare Part B uses a market-based system to pay for medicines?

PhRMA  |  Blog Post

Following implementation of the new system, the Medicare Payment Advisory Commission reported in January 2007 that “As intended by the policy, payment rates for drugs were reduced to levels closer to provider purchase prices.”

You have reviewed the first 425 results out of 1029. Each page contains 25 results. You're on page 17.

prev 13 14 15 16 17 18 next